Pfizer, Moderna and COVID-19
Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U.S. Patent Office tribunal that two patents Moderna accused them of infringing were invalid.
Investor's Business Daily on MSN2d
Why Moderna Stock Has Surged 15% This Week Despite Mixed NewsModerna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open ...
Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...
Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...
Moderna (NasdaqGS:MRNA) recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded ...
Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...
Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...
Mutual of America Capital Management LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 2.6% during the ...
Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...
Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open market. Moderna (NasdaqGS:MRNA) recently experienced a notable 10% ...
Bullish option flow detected in Moderna (MRNA) with 25,737 calls trading, 1.2x expected, and implied vol increasing almost 4 points to 82.07%.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback